Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 55154-8188

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 55154-8188). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bag Label (61d073ec 51a4 48c7 8762 25fdd00fe6ac 00)

Bag Label (61d073ec 51a4 48c7 8762 25fdd00fe6ac 00)
Sevelamer Carbonate Tablets is a prescription medication containing 800 mg of Sevelamer carbonate used to treat high blood phosphate levels. The tablets come in a pack of 10, and each tablet is film-coated. The active ingredient in the drug is Sevelamer carbonate, while the inactive ingredients include acetylated monoglycerides, ammonium hydride, black iron oxide, colloidal silicon dioxide, crospovidone, glyceryl benenate, hydroxypropyl cellulose, hypromellose, mannitol, propylene glycol, shellac glaze, and talc. It is to be stored between 20° to 25° C (68° to 77 F) and should be protected from moisture. The manufacturer of the drug is Aurobindo Pharma USA. Inc, and it is packaged by the American Health Packaging in Columbus, Ohio, and distributed by Cardinal Health in Dublin, OH 43017. The usual dosage is not provided, and users are to refer to the product insert for full prescribing information, precautions, and warnings. The package is not child-resistant, and it is intended for institutional use only, therefore, users are advised to keep the drug out of children's reach.*
FDA Label Image

Figure 3 (Sevelamer Fig1)

Figure 3 (Sevelamer Fig1)
The text is a figure caption showing the percentage of patients achieving a reduction in phosphorus levels from baseline (mg/dL) represented on the Y-axis, and the medication Sevelamer Hydrochloride on the X-axis. The figure also displays the percentage of patients experiencing an increase or reduction in serum phosphorus levels.*
FDA Label Image

Figure 4 (Sevelamer Fig2)

Figure 4 (Sevelamer Fig2)
FDA Label Image

Chemical Structure (Sevelamer Str)

Chemical Structure (Sevelamer Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.